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Hematopoietic stem and progenitor cells (HSPCs) govern the daily expansion and 23 
turnover of billions of specialized blood cells. Given their clinical utility, much effort has 24 
been made towards understanding the dynamics of hematopoietic production from this 25 
pool of stem cells. An understanding of HSC clonal dynamics during blood ontogeny 26 
could yield important insights into hematopoietic regulation, especially during aging and 27 
repeated exposure to hematopoietic stress; insults that may predispose individuals to the 28 
development of hematopoietic disease. Here, we review the current state of research 29 
regarding the clonal complexity of the hematopoietic system during embryogenesis, 30 
adulthood and hematologic disease.    31 
  32 
 3 
Introduction 33 
In humans, a pool of hematopoietic stem and progenitor cells (HSPCs) governs the daily 34 
expansion and turnover of billions of specialized blood cells. HSPCs are hierarchical in 35 
structure, with a pool of hematopoietic stem cells (HSCs) with self-renewal capacity and 36 
advanced multipotency sitting at the top that give rise to more committed and transient 37 
progenitors1,2. HSCs are classically defined by their ability to give rise to all lineages of 38 
the blood after transplantation (HSCT)1,2 and are routinely used for therapeutic purposes 39 
to treat hematologic maladies. Given the unique potency of HSPCs and HSCs and their 40 
utility in the clinic, much effort has been made towards understanding the dynamics of 41 
hematopoietic production from this pool of stem cells. An understanding of HSC clonal 42 
dynamics during blood ontogeny could yield important insights into hematopoietic 43 
regulation, especially during aging and repeated exposure to hematopoietic stress; insults 44 
that may predispose individuals to the development of hematopoietic disease. Here, we 45 
review the current state of research regarding the clonal complexity of the hematopoietic 46 
system during embryogenesis, adulthood and hematologic disease.    47 
 48 
Clonal complexity of the blood during early ontogeny 49 
Over the last six decades, the embryonic origins of hematopoiesis have been extensively 50 
studied with an eye towards developing a deep understanding of when, where and how 51 
blood precursors emerge during development3,4. The hope is that this knowledge can be 52 
leveraged to inform efforts to engineer clinical useful blood cells from differentiating 53 
pluripotent stem cells. Until recently, the actual number of cells emerging during early 54 
ontogeny to establish life-long blood production has been unclear. Here, we will focus on 55 
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reviewing recent progress towards answering this question and assessing how these 56 
numbers change over time (Table 1).  57 
 58 
The emergence of HSC during embryogenesis  59 
Several recent reviews have nicely summarized current models of hematopoietic 60 
development and HSC emergence during embryogenesis3-6. Here, we will focus most of 61 
our discussion on work in mice and zebrafish, two well-characterized models of vertebrate 62 
hematopoiesis3-5. Briefly, transplantable HSCs are first detected in murine embryos at 63 
embryonic day 10.5 (E10.5)7-10. In zebrafish, runx1+ cells are detected in the dorsal aorta 64 
by 24 hours post-fertilization (hpf)11-14 and CD34 expression (reflective of HSC 65 
emergence) is detected in the ventral endothelium of the aorta at week 5 of human 66 
gestation15,16. Briefly, the current favored model in vertebrates is that hemogenic (or blood-67 
forming) endothelium gives rise to HSCs via an endothelial to hematopoietic transition 68 
(EHT) during development17-19. EHT is characterized by the budding of hematopoietic 69 
precursors and progenitors into the lumen of the major arteries, where they form intra-70 
arterial clusters (IACs) in mice19,20 and migrate into the cardinal vein in zebrafish12. In 71 
mice, IACs mostly localize to the ventral wall of the dorsal aorta and vitelline and umbilical 72 
arteries8,15,20-22. IACs are thought to harbor nascent hematopoietic populations because 73 
embryos devoid of Runx1 expression lack IACs17,18. In mammals, HSCs migrate to the 74 
fetal liver (FL), where they are mostly found by E12.57,23. In zebrafish, they migrate to the 75 
caudal hematopoietic tissue (CHT, thought to be equivalent to the murine  FL)5,11,24. FL 76 
and CHT are considered niches supportive of HSC expansion23,25. HSCs complete their 77 
journey by moving into the bone marrow (BM) in mammals or the kidney marrow (the 78 
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equivalent to the mammalian BM) in zebrafish, where they mostly remain during adult life 79 
to support adult hematopoiesis3-5. Defining HSC dynamics during embryogenesis can 80 
illuminate precise developmental stages and tissues that affect HSC emergence, expansion 81 
or quiescence, which can direct an investigator’s focus in the hunt for signals that might be 82 
exploited to recapitulate HSC specification or expansion in vitro.  For example, the 83 
appearance of transplantable HSCs in the murine mid-gestation embryo reflects a critical 84 
time when HSCs are emerging from the hemogenic endothelium3. Thus, one might expect 85 
a focused study of this developmental stage to identify cues that promote the efficient in 86 
vitro generation of HSCs26-29. Indeed, the derivation of HSCs from endothelium or 87 
embryonic stem cells has recently been reported, albeit the process remains highly 88 
inefficient30,31.  89 
 90 
Further identification of critical developmental cues and milestones should pave the way 91 
for efficient derivation of HSCs in vitro. In the next section, we will describe approaches 92 
that have been employed to study the development of the adult HSC pool during early 93 
ontogeny. 94 
 95 
 Methodologies to study clonal complexity during embryogenesis 96 
Methodologies that employ HSC transplantation 97 
Classically, two main approaches have been taken to study the sites and dynamics of HSCs 98 
during embryogenesis: 1) Transplantation of freshly isolated embryonic tissues7,10,23,32 and 99 
2) transplantation of ex vivo cultured embryonic tissues33-37.  Most studies that estimate 100 
numbers of HSCs during embryogenesis have utilized limiting dilution transplantation into 101 
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conditioned adult recipients3,4,38,39,10,23,32,7-9,40. However, it is important to note that larger 102 
numbers of functional HSCs are detected when conditioned neonates are used as recipients, 103 
likely because newly specified HSCs engage more efficiently with a developmentally 104 
immature BM niche relative to an adult BM niche40-42. Importantly, nascent HSCs not yet 105 
developmentally mature enough to successfully engraft the bone marrow niche and/or 106 
replenish a fully ablated hematopoietic system are not detected in these types of 107 
transplantation studies, even though they may ultimately mature into a cell that contributes 108 
to life-long blood production. Hence, any estimate of the initial clonal complexity of the 109 
HSC pool obtained by transplant are biased towards numbers of mature HSCs and likely 110 
undercount the total number of true HSCs produced during early ontogeny. 111 
 112 
To overcome these limitations, Dr. Medvinsky‘s laboratory developed an elegant culture 113 
system that allows for the ex vivo maturation of E8.5-E11.5 HSC-precursors into 114 
transplantable HSCs33-36,43,44. Candidate HSC-precursors FACS sorted from dissociated 115 
tissues and reaggregated with or without OP9 stromal cells have been shown to specify 116 
transplantable HSCs de novo using this system27-30,37. This has allowed for 1) a delineation 117 
of a maturation hierarchy of HSC-precursors and 2) quantification of HSC-precursor 118 
numbers between E9.5-E10.5 when combined with limiting dilution transplantation 119 
studies34. Still, technical caveats associated with this strategy that may preclude precise 120 
estimates of HSC-precursor numbers and their dynamics must be considered. These 121 
include: the disruption of embryonic development and exposure of embryonic tissues to 122 
high [O2], stress associated with enzymatic and physical tissue dissociation and exposure 123 
of cells to non-physiological stroma (i.e. OP9 stromal cells) and concentrations of growth 124 
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factors and cytokines. In short, any system based on ex vivo culture suffers from 125 
unanswerable concerns regarding the preservation of native development. Thus, although 126 
this system is an excellent ex vivo surrogate from which many important biological insights 127 
have been derived33-36,43,44, estimates regarding HSC-precursor numbers and their 128 
dynamics are likely skewed.  Thus, the need for systems to study unperturbed 129 
hematopoiesis.  130 
 131 
Methodologies to study unperturbed hematopoiesis 132 
To avoid transplantation and stresses that could affect native embryonic hematopoiesis, 133 
investigators have recently employed in vivo labeling of HSC precursors by means of 134 
multi-color-fluorescent systems similar to those employed to study neuronal 135 
circuits37,45,46,47. We took advantage of an inducible murine Confetti allele37,46, while the 136 
Zon laboratory utilized the Zebrabow system45, to track clonal diversity of the early 137 
hematopoietic system. Both systems allow for the labeling of pools of HSC-precursors with 138 
multiple distinct fluorophores. The Cre-recombinase (CRE)-responsive Confetti allele  139 
allows for inducible labeling of blood precursors at distinct developmental stages by 140 
crossing with tissue-specific CRE alleles (e.g. mesodermal precursors can be labeled using 141 
Flk1-Cre)37. Alternatively, unbiased labeling of blood precursors at discrete developmental 142 
stages can be achieved using ubiquitously expressed ERT2-CRE alleles (e.g. Ubiquitin-143 
ERT2-Cre)37. The Zebrabow system allows one to induce labeling of a pool of cells with 144 
about 40 distinguishable fluorescent colors, while the random recombination of the 145 
Confetti allele renders only four colors45. Thus, in a liquid and polyclonal tissue like blood, 146 
the Confetti allele does not enable tracking of individual clones over time. Rather, using 147 
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mouse-to-mouse variance (MtMV) in the final distribution of Confetti-induced labeling, 148 
the gross clonal complexity of the blood can be assessed over time37. To estimate the 149 
number of blood precursors in zebrafish, drl:creERT2, which is active in early 150 
hematopoiesis, was used to induce Zebrabow-based color barcoding of HSCs and their 151 
progeny45. A hsp70l LASER-inducible method, previously employed to track microglial 152 
precursors, was also used to specifically label individual HSC precursors45,48. These models 153 
minimize disruption of embryonic hematopoiesis, score the number of HSCs present at a 154 
specific stages that realize their potential to contribute to adult blood and also capture the 155 
cumulative output of all blood progenitors to adult hematopoiesis. It would be very 156 
interesting to employ genetic-barcoding-technologies, like the Sleeping-Beauty system49, 157 
PolyLox50 or CRISPR-based molecular recording or scarring51,52 to analyze clonal 158 
dynamics in embryonic hematopoiesis. The advantage of these technologies would also be 159 
their ability to track the contribution of individual embryonic clones to the different blood 160 
lineages during adult hematopoiesis.  161 
 162 
An evolving model of embryonic clonal complexity: new questions and future 163 
challenges 164 
Classic studies solely based on transplantation suggested that at E10.5 and E11.5 of murine 165 
development,  <1  and 1-2 transplantable HSCs are detected, respectively 7-9. Around E11, 166 
HSCs and HSC precursors migrate from the AGM and major arteries into the FL, where 167 
by E12.5 most of the transplantable activity is localized7,23. At this stage, about 60 HSCs 168 
are detected in the FL7,10,23,32. The FL has long been considered a niche supportive of 169 
dramatic HSC expansion because the number of transplantable FL HSCs expands to about 170 
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1000 by E14.57-9,10,23,32. Although HSCs start their migration to the bone marrow (BM) at 171 
E15.5, very few transplantable HSCs are detectable in the BM even as late as E18.5 (5-172 
10 HSC in the long bones)3,4,38,39,53,54. As HSCs migrate into the fetal BM, their numbers 173 
increase until a plateau is reached between days 21-27 post-birth (P21-P27), which is when 174 
HSCs are thought to acquire their characteristic adult quiescent state38. At this time point, 175 
the entire mouse contains about 20,000 HSCs (as the total number of BM cells is 2x108 176 
and the frequency of HSC among them is 1 /10,00055-60).  177 
 178 
The exact cellular mechanisms (specification, symmetric versus asymmetric cell division, 179 
apoptosis etc…) leading to these numbers at each developmental stage are not well 180 
understood. EHT is widely accepted as the mechanism via which HSCs first emerge in the 181 
AGM3,4. In this model, cell division accounts for the 100-fold expansion in HSC numbers 182 
between E11.5 and E15.5 in the FL, supporting the widely accepted view that the FL 183 
constitutes an expansion niche that promotes extensive HSC self-renewal7-9,10,23,32. 184 
Recently, employing explant-reaggregate-cultures paired with limiting dilution 185 
transplantation, Medvinsky’s laboratory showed that the number of HSC precursors (pre-186 
HSC) in the AGM region matures and expands between E9.5 to E11.5 to a total of about 187 
60 pre-HSC, matching the total number of HSCs present in the FL at E12.534. This suggests 188 
that this early burst of transplantable HSC activity in the FL is due to maturation rather 189 
than cell division. This further implies that the FL supports, at most, a 16-fold expansion 190 
in HSCs between E12.5-E15.5. Recent studies by ourselves and others, as detailed below, 191 
have challenged even these more modest expansion numbers, as a larger complexity in the 192 
 10 
number of early blood forming clones was observed during the AGM stage of hemogenic 193 
specification (600)37,45.  194 
 195 
In zebrafish (physically much smaller than a mouse), the number of HSCs was originally 196 
studied in vivo by imaging of Tg(cd41:eGFP) and Tg(Runx1+23:eGFP) reporter 197 
embryos11,24. These studies revealed 2 HSCs at 48 hpf in the ventral dorsal aorta region 198 
(VDA, equivalent to the AGM region in mouse) and 5-10 HSCs at 80hpf in the CHT11,24. 199 
Zebrabow-based clonal fate mapping studies showed a more complex initial origin of the 200 
hematopoietic system. 21 pre-HSC clones were detected at 24 hpf, which is prior to HSC 201 
emergence, 28 HSC were scored at the peak of  HSC budding from the endothelium and 202 
34 HSC clones were seen by 72hpf45. The discrepancy in the numbers of HSCs detected 203 
by Tg(cd41:eGFP) and Tg(Runx1+23:eGFP) and the new clonal fate mapping strategies 204 
likely results from transgene variegation11,24,45.  205 
 206 
Similarly, our own studies suggest more complex clonal origins of the adult blood system 207 
in the mouse. We detected 600 mesodermal precursors (E7.5), 600 endothelial 208 
precursors (E8.5-E10.25) and 600 early HSCs (E11.5-E12.5) contributing to adult 209 
hematopoiesis using Flk-1-Cre, VE-cadherin-Cre and Vav1-Cre to induce Confetti labeling 210 
during these specific windows of HSC ontogeny37. Because Vav1-Cre saturates its labeling 211 
of hematopoietic cells by E12.5, it fails to capture any expansion of HSCs that may occur 212 
during later stages of FL hematopoiesis. Thus, these data suggest that up until E12.5, very 213 
little expansion occurs in the numbers of clones that contribute to life-long hematopoiesis. 214 
However, we recently used Ubiquitin-ERT2-Cre to induce Confetti labeling between E12.5 215 
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and E14.5 (M. Ganuza, unpublished data). In these studies, about 1800 clones were 216 
estimated to contribute to life-long hematopoiesis during this window. These numbers 217 
grossly match the number of HSCs detected by transplantation at E15.5 (1,000)3,4,10. 218 
These data further suggest that the FL HSC pool only expands about 3-fold between E12.5 219 
and E15.5. Although these results challenge the classic model in which the FL supports a 220 
dramatic expansion of HSCs fated to contribute to adult blood, they are consistent with a 221 
model in which the FL is a site of HSC maturation. In this scenario, nascent HSCs migrate 222 
to the FL, where they mature into transplantable HSCs. This is also consistent with 223 
Medvinsky’s findings that by E11.5 the number of HSC precursors in the AGM  matches 224 
the number of transplantable E12.5 FL HSCs34. However, phenotypic FL-HSCs are clearly 225 
actively cycling4,32,61-63. To reconcile the apparent absence of a dramatic expansion during 226 
mid-gestation in the number of cells that contribute to adult blood and the cycling FL HSC 227 
compartment, we imagine two non-mutually exclusive developmental scenarios: 1) the cell 228 
divisions of phenotypic FL-HSCs may be largely asymmetric, which would maintain a 229 
relatively constant pool of HSCs with life-long potential in the FL. Supporting this, 230 
cultured single mouse and human FL HSCs produce daughter cells which display an 231 
uneven distribution of proliferative potential and cell cycle properties, indicating a high 232 
functional heterogeneity amongst daughter cells64,65. Based on this work, Brummendorf 233 
and colleagues proposed the presence of a cell intrinsic control of stem cell fate64. 2) It is 234 
also possible that only a sub-set of FL HSCs are capable of migrating and establishing 235 
themselves in the fetal BM-niche. This process might be at least in part cell-intrinsic, given 236 
the functional heterogeneity of the FL-HSC pool64,65. Non-cell autonomous mechanisms 237 
may also be in play, such as limited BM-niche space, which could collectively constitute a 238 
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developmental bottleneck that precludes some FL HSCs from realizing their potential to 239 
contribute to life-long hematopoiesis. It is interesting that during this phase the expression 240 
levels of CXC chemokine ligand 12 (CXCL12) are cell cycle dependent, with increased 241 
levels during S/G2/M phases, concomitant with an engraftment defect38.  242 
 243 
Further studies employing non-invasive methods will be required to fully describe the 244 
dynamics of HSCs during E12.5-P7 when HSCs reside in the FL. This will be essential to 245 
definitively establish if the generally accepted role of the FL during HSC ontogeny should 246 
be revised. Is the FL truly a niche in which HSCs capable of life-long hematopoiesis 247 
dramatically expand? Is it possible that the neonatal bone marrow supports more life-long 248 
HSC expansion than the FL? Definitive answers to these questions are essential to choosing 249 
the right developmental stage to search for novel signals that might support dramatic 250 
expansion of HSCs ex vivo.  251 
 252 
Normal Aging 253 
Transplantation models reveal HSC potency declines with age 254 
The first efforts to identify the hematopoietic output of individual adult clones in vivo 255 
relied on labeling HSCs or HSPCs in vitro followed by transplantation66-68. HSCs labeled 256 
by retrovirus-mediated gene transfer were transplanted and recipient blood analyzed via 257 
Southern blot for the contribution of individual clones68,69. These studies identified 258 
“classes” of stem cells that could repopulate all hematopoietic lineages as well as stem 259 
cells appeared biased towards specific lineages69. Given that a majority of recipients were 260 
reconstituted by a small number of clones long-term post-transplant68,69, it was proposed 261 
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that any specific lineage-restricted differentiation and/or heightened turnover of clones 262 
were due to mechanisms acting on the total pool of clones, rather than the activity of 263 
discrete “classes” of stem cells68. More sensitive methods emerged for detecting virally 264 
tagged stem cells, including solid-phase primer extension with ligation-mediated PCR70, 265 
cellular barcoding71-76 and vector integration site (VIS) analysis77. Using viral genetic 266 
barcoding coupled with high-throughput sequencing, Lu et al. observed that murine 267 
HSCs contributed minimally to mature blood cells, while committed progenitors tracked 268 
closely to their expected progeny72. Naik et al. used barcoding to propose a “graded 269 
commitment” model of murine hematopoiesis. In this model, most HSCs provide 270 
progenitors for all mature cell types, but the progenitors themselves—with a focus on 271 
lymphoid-primed multipotent progenitors (LMMPs)—display heterogeneity in their 272 
differentiation output7. Cellular barcoding has been used to visualize distinct differences 273 
in the clonal output of transplanted young and old murine HSCs. For instance, by 274 
assessing peripheral blood and HSC production in recipients, the old HSC pool appeared 275 
to be comprised of many clones with ‘small’ output (also defective in lymphoid potential) 276 
relative to the young HSC pool, which although appearing to contain fewer clones, these 277 
clones were typified by a ‘large’ output74. However, similar studies assessing the effects 278 
of aging on hematopoiesis in macaques did not detect lymphoid deficiency from aged 279 
HSPCs78. Using VIS analysis in a primate model of transplantation, Kim et al. observed 280 
clonal succession of HSCs, with the most persistent clones displaying heterogeneity in 281 
lineage output77. A more recent primate study that used a barcoding strategy presented a 282 
model in which HSPCs display initial and persistent heterogeneity in lineage output76.  283 
 284 
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A part from viral tags, other methods for in vivo tracking of the clonal output of 285 
transplanted HSC clones have been applied to animal models79,80. Mathematical modeling 286 
and computer simulations based on murine transplantation data suggested that each 287 
individual HSC clone—as well as daughter HSC—has an intrinsically determined 288 
lifespan, which varies greatly between clones79. By observing the glucose 6-phosphate 289 
dehydrogenase (G6PD) phenotype post-transplant in female Safari cats coupled with 290 
computer modeling, Abkowitz et al. determined that clonal dominance of transplanted 291 
HSCs appears to be random and claimed that stochastic differentiation of clones may be 292 
responsible for the range of clonal hematopoietic patterns seen in other animal models80.  293 
In total, this work presents a landscape in which the most persistent HSC clones—294 
possibly intrinsically defined—are the main drivers of heterogeneic lineage output via 295 
progenitor production, and the pool of potent clones declines with age. However, it is 296 
important to note that transplantation-based conclusions may be misleading due to 297 
random clonal dominance of transplanted HSCs. 298 
 299 
In vivo approaches suggest new models  300 
While numerous insights into the clonal behaviors of HSCs have come from 301 
transplantation studies, it is well-documented that transplantation can impose significant 302 
stress on HSCs (reviewed extensively in81). Therefore, studies of clonal hematopoiesis 303 
utilizing non-invasive in vivo-labeling methods can be informative for the study of 304 
steady-state hematopoiesis. Using a dox-inducible hyperactive Sleeping Beauty (HSB) 305 
transposase, Sun et al. labeled individual HSPCs during steady-state and tracked the 306 
clonal dynamics of native hematopoiesis49. They determined that, unlike transplantation 307 
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in which HSCs are the long-term contributors to hematopoiesis, native hematopoiesis is 308 
controlled by thousands of long-lived progenitor clones that are successively recruited 309 
throughout the murine lifespan49.  Indeed, subsequent studies with the HSB system found 310 
that the pool of multipotent progenitor clones is hierarchically organized into uni- and 311 
oligolineage clones, with the lineage fate of HSCs during native hematopoiesis primarily 312 
megakaryocytic82. By genetically labelling Tie2+ HSCs in murine bone marrow, it was 313 
similarly observed that adult hematopoiesis is primarily sustained by less primitive 314 
“short-term” HSCs and rarely receives input from more primitive HSCs15. However, 315 
other studies that also utilized non-invasive labeling methods support a more active role 316 
for HSCs in native hematopoiesis83-86. Induced labeling in Pdzk1ip1+ adult murine 317 
HSCs—a serially transplantable HSC population less prone to mobilization—suggested 318 
that these cells give rise to other HSCs, as well as progenitors and mature blood cells and 319 
were the main drivers of native hematopoiesis83,85,86. Using the Polylox barcoding system 320 
in adult murine Tie2+ HSPCs, Pei et al. reported that myeloid-erythroid and lymphocyte 321 
development appear to be bifurcated upstream, supporting a model in which HSCs and 322 
their progeny maintain a tiered hierarchy17. Multiple additional studies using in vivo 323 
labelling of HSCs have also suggested that adult HSCs actively contribute to steady-state 324 
hematopoiesis85, and that they display a reduced ability to differentiate as they age86. 325 
Thus, there is currently no clear consensus on the contribution of HSCs to native 326 
hematopoiesis—at least in murine models. 327 
 328 
To our knowledge, Ganuza et al. is the only current study to follow the clonal complexity 329 
of the hematopoietic system throughout the mammalian lifespan87. Here, the Confetti 330 
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reporter allele (as described in the previous section)37 was utilized to label hematopoietic 331 
clones during embryogenesis and then track global clonal complexity from 2-26 months 332 
of age utilizing statistical modeling87. Clonal complexity in the peripheral blood (PB) 333 
dropped by 30% by 26 months of age. This drop was more dramatic in specific BM 334 
populations—including HSCs and multipotent progenitors (MPPs). This is likely a 335 
reflection of a reduced pool of HSC clones that have preserved their productive output 336 
with age. Interestingly, we also observed an expansion and contraction of clonal pools 337 
over the lifespan of individual mice, supporting a model of PB clonal instability and/or 338 
clonal succession during native hematopoiesis.  Finally, the clonal complexity of HSCs 339 
mirrors that of MPPs throughout life, but diverges significantly from downstream HSPCs 340 
with aging, suggesting that apex HSCs consistently give rise to MPPs throughout aging, 341 
but that downstream progenitors behave more stochastically in terms of their lineage 342 
output with age87. 343 
 344 
Human HSC clonality in aging and disease 345 
Attempts have also been made to assess clonal complexity during human hematopoiesis. 346 
Initial studies relied on X chromosome inactivation patterns in hematological 347 
malignancies and were focused on the clonal origins of leukemia88,89. For instance, 348 
Fialkow et al. assessed G6PD phenotypes in women to determine that chromic 349 
myelocytic leukemia CML was clonal in origin: single enzyme phenotypes were found in 350 
CML granulocytes but not in nonleukemic granulocytes89. More recent studies have 351 
relied on hematopoietic output from patients receiving lentiviral gene therapy via 352 
HSCT90,91. After autologous transplant of gene-corrected CD34+ HSPCs in two X-linked 353 
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adrenoleukodystrophy (ALD) patients, integration site analysis showed that 354 
hematopoietic output from transplanted cells was polyclonal 24-30 months post-355 
transplant90. In another thorough study tracking therapeutically manipulated HSPCs up to 356 
four years post-transplant in four Wiskott-Aldrich syndrome patients, it was found that 357 
hematopoietic reconstitution was initially sustained by short term HSPCs until ~6-12 358 
months, at which point steady-state hematopoiesis was maintained by HSCs and MPPs91. 359 
This study also reported that 1,600-4,300 clones were responsible for production of all 360 
PB lineage cells, with clonal output higher in the lymphoid compartment compared to the 361 
myeloid compartment91.  362 
 363 
As stated earlier, transplantation is stressful for HSPCs81, and hematopoietic clonal output 364 
during steady-state versus transplantation in animal models is highly debated49,50,83,84. 365 
Therefore, a thorough understanding of hematopoietic dynamics in humans should 366 
incorporate assays that are non-invasive and performed in healthy individuals. Catlin et 367 
al. analyzed the drift of the X-chromosome phenotype (via X-chromosome inactivation 368 
patterns) in >1,000 healthy females aged 18-100 years of age and determined that human 369 
HSCs replicate once every 40 weeks. Total numbers of HSCs appear to increase from 370 
birth until adolescence and plateau during adulthood92. By measuring telomere length 371 
distributions in granulocytes and lymphocytes from 365 healthy individuals aged 0-85 372 
years, a similar increase in HSC clones in early life with a plateau during adulthood was 373 
observed, with a skewing in HSPC potential towards the myeloid lineage with age93. 374 
 375 
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In a recent landmark study, Lee-Six et al. linked the clonal output of BM HSPCs to 376 
mature PB lineage cells in a healthy adult by assessing somatic mutations via whole-377 
genome sequencing94. They confirmed that steady-state hematopoiesis in humans results 378 
from many clones that originate during embryonic development49,50,84 and that 50,000-379 
200,000 clones contribute to native hematopoiesis in adulthood94 (similar dynamics as 380 
seen in mice by Ganuza et al.87). The authors also report the existence of hematopoietic 381 
clones with persistent myeloid and B-lymphocyte output throughout life, whereas the 382 
clonal dynamics of T-lymphocytes were less clear94.  383 
 384 
Together, these studies support a model of native hematopoiesis in humans in which 385 
clonal complexity (i.e. total number of clones) peaks during early adulthood and HSCs 386 
contribute consistently to the blood throughout life. Given the apparent plateau in total 387 
HSC clones during adulthood, the existence of age-associated hematopoietic maladies are 388 
not surprising and may reflect “renegade” clones overwhelming the aging blood system.  389 
 390 
Effects of aging and disease on clonal complexity 391 
CHIP and aging 392 
Studies of X chromosome inactivation also provided the first suggestions that normal 393 
aging is associated with the expansion of HSC clones that harbor initiating driver 394 
mutations. Studies performed by the Gilliland laboratory in 1996 detected skewing of the 395 
normally random inactivation of the maternal or paternal X chromosome in blood 396 
samples from older women (> 3:1 in 40% of women over age 60), but a normal 1:1 ratio 397 
in newborn girls 95. Nearly a decade later, next generation sequencing of 398 
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polymorphonuclear cells and buccal epithelial cells from elderly (> 65 years) women 399 
identified somatic TET2 mutations in samples that also had clonal expansion by X-400 
inactivation. TET2 mutations were found in 5.6% of 180 subjects with age associated X-401 
inactivation skewing, but were not found in 105 elderly subjects without X-inactivation 402 
skewing or in 96 subjects younger than 65 that had X-inactivation skewing96. A few years 403 
later, two large studies leveraged target capture and whole exome sequencing to evaluate 404 
for the presence of 65 – 160 leukemia-associated mutations in the blood of 12,000 and 405 
17,000 presumably healthy adults97,98. Clonal populations of blood cells with leukemia-406 
associated mutations were detected in blood samples at a mutant or variant allele 407 
frequency (VAF) as low as 2%. Both studies identified the epigenetic regulators, 408 
DNMT3A, TET2, and ASXL1 as the most common (66 – 78% of identified mutations) 409 
somatic mutations in the blood of study participants. This expansion of hematopoietic 410 
stem cell clones with acquired driver mutations in myeloid leukemia-associated genes in 411 
individuals that lacked overt hematologic disease was termed clonal hematopoiesis of 412 
indeterminate potential, or CHIP97. Consistent with the Gilliland studies, the incidence of 413 
CHIP was found to increase significantly with age, with an incidence of 2.5 - 3% in 414 
individuals under age 40 and 15 – 20% in people over 7098,99. A large whole genome 415 
sequencing study puts the incidence of clonal hematopoiesis even higher. Zink et. al. 416 
identified clonal hematopoiesis in about 50% of individuals >85 years of age100. 417 
Intriguingly, the majority of individuals with clonal hematopoiesis in this study did not 418 
carry mutations in common leukemia-associated genes. Computational modeling of 419 
clonal hematopoiesis arising from “neutral drift” operating on a small, aging population 420 
of aging HSCs led the authors to conclude that clonal hematopoiesis may be an 421 
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‘inevitable consequence’ of aging. In each of these studies, the presence of a clone with 422 
or without a driver mutation was associated with an increased risk of developing a 423 
hematologic malignancy.97,98,100 CHIP is now considered a pre-cancerous state carrying a 424 
0.5 – 1% risk of leukemic conversion per year. CHIP clones with driver mutations were 425 
also unexpectedly found to be associated with an increased risk of coronary heart disease 426 
and ischemic stroke 97.   427 
 428 
Subsequent studies have shown that more sensitive sequencing techniques can identify 429 
CHIP mutations in the blood of young, apparently healthy adults.99,101 Two separate 430 
groups have demonstrated that ultra-deep targeted sequencing can reliably detect CHIP 431 
clones with a VAF as low as 0.8% in the peripheral blood. In addition to showing an 432 
exponential increase in the prevalence of CHIP mutations with age, from 2.5% in the 20 – 433 
29 age group to over 20% in the 60 – 69 age group99,  both studies also identified age 434 
restrictions associated with a subset of genes. Mutations in DNMT3A and JAK2 were 435 
identified in individuals as young as 22, however, cancer-associated mutations in the 436 
RNA splicing factors SF3B1 and SRSF2 were only identified in subjects over age 70.99,101 437 
These findings suggest that there are likely age-associated changes to the bone marrow 438 
niche that facilitate the selection and expansion of different mutant HSC clones.    439 
 440 
CHIP in the absence of aging 441 
Although CHIP was initially defined as a feature of the aging hematopoietic system, 442 
more recent studies have identified additional hematopoietic stressors that can increase 443 
the selection and expansion of CHIP clones in “younger” adults. Studies of adults 444 
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undergoing treatment with cytotoxic chemotherapy for solid and hematologic 445 
malignancies have demonstrated a higher prevalence of CHIP and more mutations per 446 
patient compared to the general population102-104. Sequencing of 401 bone marrow 447 
samples from patients with non-Hodgkin lymphoma that received cytotoxic 448 
chemotherapy prior to autologous stem cell transplantation (SCT) identified at least one 449 
CHIP-associated mutation in 29.9% of patients102. In this study, the prevalence of CHIP 450 
was 10% in patients aged 30 to 39 and as high as 40% in patients over 60. As in age-451 
associated CHIP, 66% of patients that developed a secondary myeloid neoplasm had a 452 
detectable CHIP clone prior to SCT and patients with CHIP had a significantly inferior 453 
overall survival rate (30.4% vs 60.9%) ten years after autologous SCT. This difference 454 
was driven primarily by an increased risk of death from ischemic stroke or cardiovascular 455 
disease. At least one CHIP mutation was also identified in 25.1% of 8,810 patients with 456 
solid tumors, with a similar increase in prevalence in younger patients. Although CHIP 457 
was also associated with a statistically significant inferior overall survival in this study, 458 
the most common cause of death in these patients was disease progression. This is likely 459 
due to the aggressive nature of their primary cancers. Both studies identified a difference 460 
in the affected CHIP genes in patients that received chemotherapy, suggesting that 461 
selective pressures other than normal aging can influence clonal hematopoiesis. 462 
Mutations in the p53 pathway genes, PPM1D and TP53, were frequently identified in 463 
addition to mutations in DNMT3A, TET2, and ASXL1 in these patient populations.102,103 464 
 465 
Therapy-related CHIP 466 
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The effect of different cellular stressors on clonal hematopoiesis was further evaluated in 467 
a cohort of 119 patients with lymphoma or multiple myeloma104. Error-corrected next 468 
generation sequencing demonstrated a higher incidence of CHIP in 81 patients that 469 
received cytotoxic chemotherapy compared to 38 patients that did not receive 470 
chemotherapy. Consistent with the initial mutation developing in an HSC, CHIP 471 
mutations were detected in sorted myeloid (monocytes) and lymphoid (T cells) cells. 472 
Although the incidence was lower, mutations in DNMT3A or TET2 could be identified in 473 
aged-matched “healthy” donors as well as patients with hematologic malignancies, 474 
however, CHIP clones with TP53 or PPM1D mutations appeared to have a fitness 475 
advantage and were enriched in patients that received cytotoxic chemotherapy. In 476 
addition to the replicative stress induced by chemotherapy, autologous SCT also alters the 477 
bone marrow microenvironment, which may further select for HSCs that have acquired a 478 
competitive advantage. CHIP clones were followed for 6 – 12 months after autologous 479 
SCT in 40 of the lymphoma patients. Most CHIP clones engrafted with a VAF similar to 480 
the pre-SCT sample, however 33% of DNMT3A CHIP clones expanded more than 2-fold 481 
after engraftment and 30% of PPM1D CHIP clones decreased after SCT. Targeted next 482 
generation sequencing of 500 “healthy” related SCT donors age ≥ 55 identified CHIP 483 
clones in 16% of donors for allogeneic SCT.105 Not unexpectedly, DNMT3A, TET2, and 484 
ASXL1 were the most frequently mutated genes. Donor-derived CHIP was associated 485 
with an increased risk of chronic graft vs host disease and serial sequencing of 22 486 
recipients with donor-derived CHIP revealed clonal expansion (11 recipients) or stable 487 
engraftment (10 recipients) of the mutant clones. Notably, the recipient’s leukemia 488 
relapsed in half of the patients with linear expansion and only 2 recipients with expanding 489 
 23 
clones developed donor-cell leukemia notable for clonal evolution and the acquisition of 490 
additional mutations in myeloid leukemia genes. In a smaller study of donor-engrafted 491 
CHIP in allogeneic SCT recipients, DNMT3A mutations were identified in 5 of the 6 SCT 492 
recipients with unexplained cytopenias.106 These studies suggest that the higher incidence 493 
of CHIP in younger patients undergoing cancer treatment may be due to the selection of 494 
HSC clones with CHIP mutations that confer a growth advantage in response to different 495 
cellular stressors. 496 
 497 
Inflammatory stress and CHIP 498 
Hematopoietic stress caused by chronic inflammation has also been shown to have 499 
distinct effects on clonal dynamics.  Aplastic anemia is an acquired autoimmune disorder 500 
that results in the immune mediated destruction of bone marrow HSCs. Clonal patterns of 501 
X-inactivation have been noted in female patients with aplastic anemia.107 The risk of 502 
developing MDS or AML in aplastic anemia patients treated with immunosuppressive 503 
therapy has been shown to be as high as 15% and independent of treatment with growth 504 
factors such as G-CSF108,109. Targeted deep sequencing of peripheral blood identified 505 
CHIP mutations in 36% of a cohort of 439 patients aged 2 – 88 years with moderate to 506 
severe aplastic anemia.110 Although the prevalence of mutations increased with age, 507 
mutations in BCOR or BCORL1 and PIGA were more common than mutations in the age-508 
associated CHIP genes, DNMT3A and ASXL1. Mutations in these 5 genes accounted for 509 
77% of identified CHIP mutations in aplastic anemia and the underrepresentation of 510 
TET2, JAK2, and TP53 suggests a different mechanism of clonal selection occurs in an 511 
aplastic bone marrow microenvironment. Serial sampling found BCOR, BCORL1, and 512 
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PIGA mutant clones decreased or remained stable over time. These mutations were 513 
independently associated with a better response to immunosuppressive therapy and 514 
higher overall and progression-free survival. In contrast, DNMT3A and ASXL1 mutant 515 
clones tended to increase in size over time and were associated with worse outcome. 516 
However, clonal dynamics as whole were highly variable and did not consistently predict 517 
response to immunosuppressive therapy or long-term survival among individual patients 518 
 519 
Stress hematopoiesis, inflammation, and chronic immune stimulation leading to the 520 
selection of HSC clones with CHIP mutations may also explain the increased risk of 521 
myeloid malignancies identified in patients with autoimmune diseases. Distinct from 522 
lymphoproliferative disorders, secondary leukemias that develop in patients with 523 
autoimmune diseases are far more likely to be myeloid rather than lymphoid in nature. 524 
Two large population based studies have identified a 1.2 to 1.7 fold higher risk of 525 
developing acute myeloid leukemia (AML) and a 1.5 to 2.1 fold higher risk of developing 526 
myelodysplastic syndrome (MDS) in patients with autoimmune disease compared to the 527 
general population111,112. This increase in AML and MDS risk was initially thought to be 528 
secondary to the cytotoxic treatments used to treat autoimmune diseases, however 529 
numerous studies have since shown that leukemia risk is not associated with specific 530 
treatments with the exception of cyclophosphamide, azathioprine, and mitoxantrone. 531 
(reviewed extensively in 113) The Engels study compared 13,486 patients over age 67 532 
with myeloid malignancies to 160,086 population-based matched controls and identified 533 
several systemic autoimmune diseases, namely rheumatoid arthritis (RA), systemic lupus 534 
erythematosus (SLE), polymyalgia rheumatica, autoimmune hemolytic anemia, systemic 535 
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vasculitis, ulcerative colitis, and pernicious anemia, that were associated with a 536 
significantly increased risk of AML (odds ratio 1.57 to 6.23). RA and pernicious anemia 537 
patients also had a significantly increased risk of MDS (odds ratio 1.52 – 2.38)111.  538 
 539 
Smaller studies have shown that the risk of developing a myeloid neoplasm is associated 540 
with chronicity and severity of the autoimmune disease114. This could be consistent with 541 
the expansion of a CHIP clone that acquires additional mutations. Two recent studies 542 
have examined the incidence of CHIP in patients with autoimmune disorders. One study 543 
of 59 patients with RA (mean age 54.7 years) identified CHIP clones in 17% of 544 
participants, with a prevalence of 25% in patients over 70. They note that this is not 545 
significantly different from the incidence of CHIP in the general population and found 546 
mutations in DNMT3A, TET2, and ASXL1 to be the most common115. A slightly larger 547 
study of 112 patients with antineutrophil cytoplasmic antibodies (ANCA)-associated 548 
autoimmune vasculitis aged 18 to 84 identified CHIP in 30.4% of subjects; a much higher 549 
prevalence than an age matched cohort116. The youngest participant with CHIP was 18 550 
years old, however the median age of patients with CHIP was higher than CHIP negative 551 
patients (70.5 compared to 63.0 years). Mutations in DNMT3A, TET2, and ASXL1 were 552 
found in 63% of CHIP positive participants. Clone size was serially followed, range 3 to 553 
100 months, in 19 participants with available samples. Most clones (12) remained stable 554 
and 5 clones increased in size.  No differences in peripheral blood counts or 555 
cardiovascular disease incidence were noted between CHIP positive and negative 556 
subjects.  557 
 558 
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Taken together, the deep sequencing studies described above have demonstrated that 559 
cellular stressors associated with aging, chemotherapy, and inflammation can lead to the 560 
clonal selection of HSCs with mutations in myeloid malignancy genes that confer an 561 
increased risk of MDS/AML or cardiovascular disease. Chemotherapy and inflammatory 562 
bone marrow stress from conditions such as aplastic anemia strongly select for specific 563 
mutations (PPM1D, TP53, BCOR, BCORL1, PIGA) in addition to the genes commonly 564 
mutated during aging (DNMT3A, TET2, and ASXL1). Of note, clonal hematopoiesis due 565 
to revertant somatic mosaicism, spontaneous correction of a pathogenic allele, has also 566 
been identified as a mechanism to partially restore normal hematopoiesis in several 567 
hypocellular bone marrow failure syndromes, including aplastic anemia.117 PCR analysis 568 
of FANCA exon 29 revealed the absence of a maternal mutation in multiple mature blood 569 
cell lineages and HSPCs in a patient with Fanconi Anemia, although the mutation was 570 
present in fibroblasts.118 Single nucleotide polymorphism (SNP)-array based analysis of 571 
peripheral blood from 306 patients with aplastic anemia identified copy number-neutral 572 
loss of heterozygosity at chromosome 6p (6pLOH), leading to loss of one HLA haplotype 573 
and presumably escape from cytotoxic T cell recognition, in 40 patients (13%).117 SNP-574 
array analysis also identified spontaneous correction of an autosomal dominant 575 
pathologic TERC mutation in multiple blood lineages, but not in other tissues, in six 576 
individuals from four families with dyskeratosis congenita.119 More recently, targeted 577 
deep sequencing identified acquired stop-gain mutations in two patients with SAMD9L-578 
mutant familial MDS. These patients had a transient monosomy 7 clone that was replaced 579 
by a large somatic clone with paternal 7q uniparental disomy.120 Whereas normal 580 
hematopoiesis and thus incomplete penetrance is one of the main findings in patients with 581 
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revertant SAMD9L or TERC mutations,119,120 the patient with Fanconi Anemia also 582 
developed clones with leukemia driver mutations in non-revertant cells,118 and 6pLOH  583 
HSCs cannot repopulate the bone marrow of aplastic anemia patients without 584 
immunosuppressive therapy, which also targets the inflamed bone marrow 585 
microenvironment.117 These studies again highlight how inflammation can lead to the 586 
expansion of HSCs clones with pathologic mutations.   587 
 588 
Modeling CHIP in animals 589 
Mouse models of CHIP mutations commonly identified in humans have been used to gain 590 
further insight into the pathophysiology of CHIP and evaluate potential treatments. 591 
Mutations in DNMT3A, TET2, ASXL1, and JAK2 were commonly identified in four case-592 
control studies of a total of 4276 older individuals (age 60 to 70) with cardiovascular 593 
disease compared to 3529 controls)121. Two independent groups used Tet2-deficient 594 
(Tet2-/-) murine HSCs to study the effect of the second most commonly mutated gene in 595 
CHIP on coronary heart disease121,122. Fuster et. al. transplanted lethally irradiated 596 
atherosclerosis prone, low-density lipoprotein receptor-deficient (Ldlr-/-) mice with 10% 597 
Tet2-/- CD45.2+ HSPCs and 90% wild type (Tet2+/+) CD45.1+ HSPCs and then fed the 598 
recipient mice a high-fat/high-cholesterol diet to promote atherosclerosis development. 599 
As expected, clonal expansion of Tet2-/- HSPCs, indicated by peripheral blood CD45.2 600 
chimerism, increased from 28% CD45.2+ cells at 4 weeks post-transplant to 56% 601 
CD45.2+ cells at 12 weeks post-transplant without an effect on blood cell counts. Notably, 602 
plaques in the aortic root of Tet2-/- HSPC recipients 12 weeks after SCT were 60% larger 603 
than the plaques in wild type controls. Analysis of aortic wall immune cells was notable 604 
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for clonal expansion of immune cells with 62% CD45.2+ macrophages. Jaiswal et. al. 605 
made similar findings and both groups demonstrated that Tet2-/- macrophages aberrantly 606 
overexpress proinflammatory cytokines121,122 Fuster et. al. went on to show that an 607 
inhibitor of the NLRP3 inflammasome (MCC950) decreased interleukin-1 production 608 
by TET2-deficient macrophages and that MCC950 decreased atherosclerotic plaque size 609 
in Tet2-/- HSPC recipients by ~50% without affecting the expansion of TET2-deficient 610 
cells.122   611 
 612 
Conclusions 613 
HSC clonal dynamics after development vary greatly in response to aging and disease. 614 
Targeted sequencing has identified CHIP mutations in several different contexts, however 615 
additional studies are needed to define the genes commonly mutated in autoimmune 616 
disorders such as SLE, where CHIP clones may affect morbidity and mortality 617 
independently of the primary disease, and other conditions associated with chronic 618 
systemic inflammation such as type 2 diabetes or sickle cell disease. Targeted sequencing 619 
provides data at discrete time points and further work with animal models of CHIP 620 
mutations and chronic inflammation will be needed to improve our understanding of HSC 621 
clonal dynamics in response to disease and inform how these clones should be monitored 622 
and/or treated.   623 
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